These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33914406)

  • 1. FVIII inhibitors display FV-neutralizing activity in the prothrombin time assay.
    Arsiccio A; Beavis J; Raut S; Coxon CH
    J Thromb Haemost; 2021 Aug; 19(8):1907-1913. PubMed ID: 33914406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desmopressin acetate as a haemostatic elevator in individuals with combined deficiency of factors V and VIII: a clinical trial.
    Mansouritorghabeh H; Shirdel A
    J Thromb Haemost; 2016 Feb; 14(2):336-9. PubMed ID: 26599105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A.
    Müller J; Pekrul I; Pötzsch B; Berning B; Oldenburg J; Spannagl M
    Thromb Haemost; 2019 Sep; 119(9):1384-1393. PubMed ID: 31203578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hybrid human-porcine factor VIII proteins partially escape the inhibitory effects of anti-factor VIII inhibitor alloantibodies having A2 or C2 domain specificity.
    Mizumachi K; Nakajima Y; Shimonishi N; Furukawa S; Ogiwara K; Takeyama M; Nogami K
    Haemophilia; 2024 Jan; 30(1):140-150. PubMed ID: 38058226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
    J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII-equivalence.
    Leksa NC; Aleman MM; Goodman AG; Rabinovich D; Peters R; Salas J
    J Thromb Haemost; 2019 Jul; 17(7):1044-1052. PubMed ID: 30887655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.
    Quade-Lyssy P; Abriss D; Milanov P; Ungerer C; Königs C; Seifried E; Schüttrumpf J
    J Thromb Haemost; 2014 Nov; 12(11):1861-73. PubMed ID: 25224783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
    Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
    J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mathematical model of coagulation under flow identifies factor V as a modifier of thrombin generation in hemophilia A.
    Link KG; Stobb MT; Sorrells MG; Bortot M; Ruegg K; Manco-Johnson MJ; Di Paola JA; Sindi SS; Fogelson AL; Leiderman K; Neeves KB
    J Thromb Haemost; 2020 Feb; 18(2):306-317. PubMed ID: 31562694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.
    Chao BN; Baldwin WH; Healey JF; Parker ET; Shafer-Weaver K; Cox C; Jiang P; Kanellopoulou C; Lollar P; Meeks SL; Lenardo MJ
    J Thromb Haemost; 2016 Feb; 14(2):346-55. PubMed ID: 26588198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
    Doshi BS; Gangadharan B; Doering CB; Meeks SL
    PLoS One; 2012; 7(10):e48172. PubMed ID: 23144741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-center validation of assays for the detection of binding and neutralizing anti-factor VIII antibodies.
    Müller J; Neimanis S; Kahle J; Albert T; Schultze Strasser S; Rup B; Pötzsch B; Königs C; Oldenburg J;
    Haemophilia; 2024 Jan; 30(1):224-231. PubMed ID: 37824540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study.
    Türkantoz H; Königs C; Knöbl P; Klamroth R; Holstein K; Huth-Kühne A; Heinz J; Eichler H; Tiede A
    J Thromb Haemost; 2020 Jan; 18(1):36-43. PubMed ID: 31448877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy.
    Zhang F; Yan X; Li M; Hua B; Xiao X; Monahan PE; Sun J
    Hum Gene Ther; 2020 Apr; 31(7-8):448-458. PubMed ID: 32079420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spectrum of neutralizing and non-neutralizing anti-FVIII antibodies in a nationwide cohort of 788 persons with hemophilia A.
    Oomen I; Verhagen M; Miranda M; Allacher P; Beckers EAM; Blijlevens NMA; van der Bom JG; Coppens M; Driessens M; Eikenboom JCJ; Fijnvandraat K; Hassan S; van Heerde WL; Hooimeijer HL; Jansen JH; Kaijen P; Leebeek FWG; Meijer D; Paul H; Rijpma SR; Rosendaal FR; Smit C; van Vulpen LFD; Voorberg J; Schols SEM; Gouw SC
    Front Immunol; 2024; 15():1355813. PubMed ID: 38455035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-idiotype monoclonal antibodies against emicizumab enable accurate procoagulant and anticoagulant assays, irrespective of the test base, in the presence of emicizumab.
    Ogiwara K; Furukawa S; Shinohara S; Tabuchi Y; Arai N; Noguchi-Sasaki M; Soeda T; Shima M; Nogami K
    Haemophilia; 2023 Jan; 29(1):329-335. PubMed ID: 36137299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.
    Boylan B; Rice AS; Dunn AL; Tarantino MD; Brettler DB; Barrett JC; Miller CH; ;
    J Thromb Haemost; 2015 Jan; 13(1):47-53. PubMed ID: 25354263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.